Editas Medicine, Inc. (EDIT) stock
EDITNasdaqBiological Products, (No Diagnostic Substances)Fiscal year ends December 31
Financials through Q3 FY2026, quarter ended Sep 30, 2026Last filing: 10-Q on Nov 9, 2026Score 3/3047% above fair value
$2.38−0.13 (-4.99%)
Close on Nov 11, 2026Market cap $365.52MP/E –Yield –
Editas Medicine r&d expenses
Research and development expenses are spending on new products and technology.
Editas Medicine's R&D Expenses for the twelve months ending Sep 30, 2026 was $86.35M, down 22.3% year over year. For fiscal 2025 it was $89.95M, down 54.9% from the year before. Over ten years it grew 16.9% a year on average. The highest annual figure on record is $199.25M in fiscal 2024.
Annual r&d expenses
| Period | Period end | Value | Change |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $89.95M | -54.9% |
| FY2024 | Dec 31, 2024 | $199.25M | +12.2% |
| FY2023 | Dec 31, 2023 | $177.65M | +1.5% |
| FY2022 | Dec 31, 2022 | $174.96M | +22.8% |
| FY2021 | Dec 31, 2021 | $142.51M | -9.8% |
| FY2020 | Dec 31, 2020 | $158.00M | +63.1% |
| FY2019 | Dec 31, 2019 | $96.90M | +6.9% |
| FY2018 | Dec 31, 2018 | $90.65M | +9.0% |
| FY2017 | Dec 31, 2017 | $83.16M | +45.9% |
| FY2016 | Dec 31, 2016 | $56.98M | +202.3% |
| FY2015 | Dec 31, 2015 | $18.85M | +271.5% |
| FY2014 | Dec 31, 2014 | $5.07M | – |
Quarterly r&d expenses
Change is against the same quarter a year earlier.
| Period | Period end | Value | Change |
|---|---|---|---|
| Q3 FY2026 | Sep 30, 2026 | $21.17M | +7.1% |
| Q2 FY2026 | Jun 30, 2026 | $20.18M | +24.7% |
| Q1 FY2026 | Mar 31, 2026 | $17.60M | -33.8% |
| Q4 FY2025 | Dec 31, 2025 | $27.40M | -43.6% |
| Q3 FY2025 | Sep 30, 2025 | $19.78M | -58.5% |
| Q2 FY2025 | Jun 30, 2025 | $16.18M | -70.2% |
| Q1 FY2025 | Mar 31, 2025 | $26.59M | -45.5% |
| Q4 FY2024 | Dec 31, 2024 | $48.61M | -30.1% |
| Q3 FY2024 | Sep 30, 2024 | $47.64M | +17.6% |
| Q2 FY2024 | Jun 30, 2024 | $54.21M | +82.0% |
| Q1 FY2024 | Mar 31, 2024 | $48.79M | +29.1% |
| Q4 FY2023 | Dec 31, 2023 | $69.56M | +33.8% |
| Q3 FY2023 | Sep 30, 2023 | $40.51M | -2.0% |
| Q2 FY2023 | Jun 30, 2023 | $29.78M | -31.8% |
| Q1 FY2023 | Mar 31, 2023 | $37.80M | -0.5% |
| Q4 FY2022 | Dec 31, 2022 | $52.00M | +38.5% |
| Q3 FY2022 | Sep 30, 2022 | $41.33M | +41.2% |
| Q2 FY2022 | Jun 30, 2022 | $43.66M | +29.3% |
| Q1 FY2022 | Mar 31, 2022 | $37.98M | -9.4% |
| Q4 FY2021 | Dec 31, 2021 | $37.55M | -38.9% |
| Q3 FY2021 | Sep 30, 2021 | $29.27M | -13.7% |
| Q2 FY2021 | Jun 30, 2021 | $33.75M | +20.5% |
| Q1 FY2021 | Mar 31, 2021 | $41.94M | +21.3% |
| Q4 FY2020 | Dec 31, 2020 | $61.50M | +76.8% |
| Q3 FY2020 | Sep 30, 2020 | $33.92M | +49.4% |
| Q2 FY2020 | Jun 30, 2020 | $28.01M | +18.8% |
| Q1 FY2020 | Mar 31, 2020 | $34.57M | +118.2% |
| Q4 FY2019 | Dec 31, 2019 | $34.79M | +81.2% |
| Q3 FY2019 | Sep 30, 2019 | $22.70M | +30.1% |
| Q2 FY2019 | Jun 30, 2019 | $23.57M | -28.0% |
| Q1 FY2019 | Mar 31, 2019 | $15.84M | -25.6% |
| Q4 FY2018 | Dec 31, 2018 | $19.19M | -27.4% |
| Q3 FY2018 | Sep 30, 2018 | $17.44M | -14.5% |
| Q2 FY2018 | Jun 30, 2018 | $32.72M | +88.9% |
| Q1 FY2018 | Mar 31, 2018 | $21.30M | +12.0% |
| Q4 FY2017 | Dec 31, 2017 | $26.42M | -1.5% |
| Q3 FY2017 | Sep 30, 2017 | $20.40M | – |
| Q2 FY2017 | Jun 30, 2017 | $17.32M | – |
| Q1 FY2017 | Mar 31, 2017 | $19.02M | – |
| Q4 FY2016 | Dec 31, 2016 | $26.84M | – |
See a number that looks wrong?